[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Leiomyosarcoma - Pipeline Review, H2 2019

November 2019 | 528 pages | ID: L8402E47536EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Leiomyosarcoma - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H2 2019, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Unknown stages are 1, 14, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Leiomyosarcoma - Overview
Leiomyosarcoma - Therapeutics Development
Leiomyosarcoma - Therapeutics Assessment
Leiomyosarcoma - Companies Involved in Therapeutics Development
Leiomyosarcoma - Drug Profiles
Leiomyosarcoma - Dormant Projects
Leiomyosarcoma - Discontinued Products
Appendix

LIST OF TABLES

Number of Products under Development for Leiomyosarcoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2019
Leiomyosarcoma - Pipeline by ALX Oncology Inc, H2 2019
Leiomyosarcoma - Pipeline by Apexigen Inc, H2 2019
Leiomyosarcoma - Pipeline by Apollomics Inc, H2 2019
Leiomyosarcoma - Pipeline by AstraZeneca Plc, H2 2019
Leiomyosarcoma - Pipeline by Atara Biotherapeutics Inc, H2 2019
Leiomyosarcoma - Pipeline by BeiGene Ltd, H2 2019
Leiomyosarcoma - Pipeline by BioMed Valley Discoveries Inc, H2 2019
Leiomyosarcoma - Pipeline by Cell Medica Ltd, H2 2019
Leiomyosarcoma - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
Leiomyosarcoma - Pipeline by Eli Lilly and Co, H2 2019
Leiomyosarcoma - Pipeline by Exelixis Inc, H2 2019
Leiomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Leiomyosarcoma - Pipeline by Incyte Corp, H2 2019
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2019
Leiomyosarcoma - Pipeline by Merck & Co Inc, H2 2019
Leiomyosarcoma - Pipeline by Merck KGaA, H2 2019
Leiomyosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Leiomyosarcoma - Pipeline by Nektar Therapeutics, H2 2019
Leiomyosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Leiomyosarcoma - Pipeline by Pfizer Inc, H2 2019
Leiomyosarcoma - Pipeline by PTC Therapeutics Inc, H2 2019
Leiomyosarcoma - Pipeline by Tactical Therapeutics Inc, H2 2019
Leiomyosarcoma - Pipeline by Vicus Therapeutics LLC, H2 2019
Leiomyosarcoma - Pipeline by Y-mAbs Therapeutics Inc, H2 2019
Leiomyosarcoma - Pipeline by Yooyoung Pharm Co Ltd, H2 2019
Leiomyosarcoma - Dormant Projects, H2 2019
Leiomyosarcoma - Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development for Leiomyosarcoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Advenchen Laboratories LLC
ALX Oncology Inc
Apexigen Inc
Apollomics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
BeiGene Ltd
BioMed Valley Discoveries Inc
Cell Medica Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Karyopharm Therapeutics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Nektar Therapeutics
Ono Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
Tactical Therapeutics Inc
Vicus Therapeutics LLC
Y-mAbs Therapeutics Inc
Yooyoung Pharm Co Ltd


More Publications